The key role of the RyR2in serious diseases such as CPVT has identified the RyR2 as a potentialdrug target, but the lack of a clear mechanism that describes channelgating has remained a roadblock in the development of new pharmacologicalagents.19,20. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.